Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Diffuse large B-cell lymphoma is an aggressive cancer, but it is treatable. The initial treatment often puts it into remission, which means there are no longer any signs or symptoms of the cancer.

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Opens in a new tab or window Follicular lymphoma is an indolent malignancy ... follicular lymphoma into a more aggressive lymphoma -- diffuse large B-cell lymphoma." Thus, "it is important that ...

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, ...

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

"Full House" star Dave Coulier revealed this week that he is cancer-free after undergoing chemotherapy following a diagnosis ...